SEC Form 6-K filed by Anbio Biotechnology
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2025
Commission File Number: 001-42526
Anbio Biotechnology
Friedrich-Ebert-Anlage 35-37, 60327
Frankfurt am Main,
Germany
+49 69870039170
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On December 30, 2025, Anbio Biotechnology, a Cayman Islands exempted company issued a press release entitled “Anbio Biotechnology Announced Unaudited Financial Results for the Six Months Ended June 30, 2025.” A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release - Anbio Biotechnology Announced Unaudited Financial Results for the Six Months Ended June 30, 2025 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Anbio Biotechnology | ||
| Date: December 30, 2025 | By: | /s/ Michael Lau |
| Name: | Michael Lau | |
| Title: | Chief Executive Officer | |
2